| pubmed-article:19434048 | pubmed:abstractText | Anemia remains an early and common complication of chronic kidney disease that causes troubling symptoms and reduced quality of life. Recent literature has raised concern about the safety of erythropoiesis-stimulating agent (ESA) treatment to higher hemoglobin targets, making this an ideal time to review this subject. In addition, new drugs are being developed in both the ESA and intravenous (i.v.) iron classes. | lld:pubmed |
